Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Laboratory for Molecular Medicine, |
RCV000825997 | SCV000967485 | uncertain significance | not specified | 2018-09-17 | criteria provided, single submitter | clinical testing | The p.Ala1518Thr variant in OTOF has not been previously reported in individuals with hearing loss or auditory neuropathy spectrum disorder but has been identif ied in 0.058% (14/24028) African chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org). Computational prediction tools and c onservation analysis suggest that the p.Ala1518Thr variant may not impact the pr otein, though this information is not predictive enough to rule out pathogenicit y. In summary, the clinical significance of the p.Ala1518Thr variant is uncertai n. ACMG/AMP Criteria applied: BP4, PM2_Supporting. |
Gene |
RCV001772151 | SCV001994595 | uncertain significance | not provided | 2024-06-10 | criteria provided, single submitter | clinical testing | In silico analysis indicates that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |
Ambry Genetics | RCV002536074 | SCV003728554 | uncertain significance | Inborn genetic diseases | 2021-07-21 | criteria provided, single submitter | clinical testing | The c.4552G>A (p.A1518T) alteration is located in exon 37 (coding exon 37) of the OTOF gene. This alteration results from a G to A substitution at nucleotide position 4552, causing the alanine (A) at amino acid position 1518 to be replaced by a threonine (T). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Labcorp Genetics |
RCV001772151 | SCV004284462 | benign | not provided | 2023-12-18 | criteria provided, single submitter | clinical testing |